Contrasting Pivot Pharmaceuticals (PVOTF) & Puma Biotechnology (PBYI)

Pivot Pharmaceuticals (OTCMKTS:PVOTF) and Puma Biotechnology (NASDAQ:PBYI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.


This table compares Pivot Pharmaceuticals and Puma Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pivot Pharmaceuticals N/A -167.47% -77.73%
Puma Biotechnology -73.45% -295.69% -78.31%

Institutional & Insider Ownership

92.5% of Puma Biotechnology shares are held by institutional investors. 36.0% of Pivot Pharmaceuticals shares are held by company insiders. Comparatively, 21.5% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Pivot Pharmaceuticals and Puma Biotechnology’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pivot Pharmaceuticals N/A N/A -$120,000.00 N/A N/A
Puma Biotechnology $26.20 million 29.13 -$291.95 million ($7.85) -2.56

Pivot Pharmaceuticals has higher earnings, but lower revenue than Puma Biotechnology.

Analyst Ratings

This is a summary of current ratings and price targets for Pivot Pharmaceuticals and Puma Biotechnology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pivot Pharmaceuticals 0 0 0 0 N/A
Puma Biotechnology 4 2 5 0 2.09

Puma Biotechnology has a consensus target price of $74.80, indicating a potential upside of 272.70%. Given Puma Biotechnology’s higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than Pivot Pharmaceuticals.


Pivot Pharmaceuticals beats Puma Biotechnology on 5 of the 9 factors compared between the two stocks.

Pivot Pharmaceuticals Company Profile

Pivot Pharmaceuticals Inc., a development stage pharmaceutical and nutraceutical company, engages in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using drug delivery platform technologies in Canada. The company offers its products for cancer supportive care, pain and inflammation, women's sexual dysfunction, dermatology, and eye diseases. It also focuses on the research, development, and commercialization of cannabinoid based nutraceuticals. The company was formerly known as Neurokine Pharmaceuticals Inc. and changed its name to Pivot Pharmaceuticals Inc. in April 2015. Pivot Pharmaceuticals Inc. was founded in 2002 and is based in Vancouver, Canada.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Receive News & Ratings for Pivot Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pivot Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply